Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech to Run Qiagen Respiratory Test on MDx Platform

NEW YORK (GenomeWeb News) – Osmetech said today that it will adapt a Qiagen respiratory viral test for use on its eSensor XT-8 molecular diagnostics system.
 
Qiagen will supply Osmetech with its QIAplex-based reagents for the multiplex amplification of the most common viruses associated with respiratory infections. UK-based Osmetech said that it will develop an in vitro diagnostic test for use on its molecular diagnostics platform and submit the test for US Food and Drug Administration clearance.
 
This past summer, Qiagen launched its QIAplex-based ResPlex II respiratory panel for research use only. The panel enables detection of up to 17 different viral molecular targets, including influenza A/B and parainfluenza RSV A/B.
 
“This is an excellent opportunity to take an already commercially successful product into the mainstream diagnostics market,” Osmetech CEO James White said in a statement.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.